Skip to main content
. 2021 Oct 13;9(12):1396–1406. doi: 10.1016/S2213-2600(21)00402-1

Figure 2.

Figure 2

Solicited local (A) and systemic (B) adverse events occurring within 7 days of the first and second doses of MVC-COV1901 or placebo

Adverse events were graded as mild (grade 1), moderate (grade 2), or severe (grade 3).